At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,913 enrolled
Drug / intervention
Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)drug
Likely dose
Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RESPECT: Observational, Prospective, Open-label, Multi-center Study Evaluating the Antihypertensive Effect of Treatment With Telmisartan (Alone or in Fixed Combination With HCTZ) in General Practitioner and Specialist Practice in Hypertensive Patients With High and Very High Cardiovascular Risk According to the ESH/ESC Guidelines 2007 Who Are Uncontrolled Under Current Treatment.
In Brief
An observational study evaluating Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ) for Hypertension. Completed, enrolled 2,913 participants.
Detailed Summary
To assess the efficacy of telmisartan in hypertensive patients with high cardiovascular risk
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2009
Primary CompletionDec 2009
TodayJul 2026
First PostedApr 29, 2009
Enrollment StartApr 1, 2009
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.2 years ago
Interventions
Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)drug
Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg